Search

Your search keyword '"EXTRACHROMOSOMAL DNA"' showing total 114 results
Start Over Descriptor "EXTRACHROMOSOMAL DNA" Database Gale General OneFile
114 results on '"EXTRACHROMOSOMAL DNA"'

1. Enhancer activation from transposable elements in extrachromosomal DNA

Subjects
Transposons, Colorectal cancer, Extrachromosomal DNA, Physical fitness, Health
Abstract

2024 SEP 28 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- According to news reporting based on a preprint abstract, our journalists obtained [...]

Published
2024

5. Boundless Bio intiated with Not Rated at Goldman Sachs

Subjects
The Goldman Sachs Group Inc., Investment banks, Extrachromosomal DNA, Business, News, opinion and commentary
Abstract

Goldman Sachs analyst Chris Shibutani initiated coverage of Boundless Bio with a Not Rated and no price target. Boundless is a clinical-stage biotechnology company dedicated to developing oncology therapeutics for [...]

Published
2024

6. Boundless Bio presents preclinical data on BBI-355

Subjects
Extrachromosomal DNA, Business, News, opinion and commentary
Abstract

Boundless Bio presents preclinical and clinical pharmacodynamic data on its lead ecDNA-directed therapy, BBI-355, and research on ecDNA-mediated acquired resistance to chemotherapy at the American Association for Cancer Research Annual [...]

Published
2024

7. Boundless Bio opens at $14.25, IPO priced at $16 per share

Subjects
Going public (Securities), Cancer -- Genetic aspects, Extrachromosomal DNA, Company public offering, Company securities, Business, News, opinion and commentary
Abstract

Boundless Bio (BOLD) priced 6.25M shares at $16.00. The deal priced at the midpoint of the $15.00-$17.00 target range. Boundless Bio is a clinical stage oncology company interrogating extrachromosomal DNA, [...]

Published
2024

8. Boundless Bio indicated to open at $17.50, IPO priced at $16

Subjects
The Goldman Sachs Group Inc. -- Securities, Going public (Securities), Investment banks, Cancer -- Genetic aspects, Extrachromosomal DNA, Company public offering, Company securities, Business, News, opinion and commentary
Abstract

Boundless Bio (BOLD) priced 6.25M shares at $16.00. The deal priced at the midpoint of the $15.00-$17.00 target range. Goldman Sachs, Leerink, Piper Sandler and Guggenheim are acting as joint [...]

Published
2024

10. CytoCellDB: A Resource Database For Classification and Analysis of Extrachromosomal DNA in Cancer

Subjects
Cytogenetics, Drug resistance, Databases, Cancer -- Genetic aspects, Extrachromosomal DNA, Chromosomes, Physical fitness, CD-ROM catalog, Database, CD-ROM database, Health
Abstract

2024 JAN 6 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- According to news reporting based on a preprint abstract, our journalists obtained [...]

Published
2024

12. Baylor College of Medicine Researchers Publish New Data on Science (Yeast EndoG prevents genome instability by degrading extranuclear DNA species)

Subjects
Biochemistry, Genomics, Genetic research, Extrachromosomal DNA, DNA binding proteins, Mitochondrial DNA, Health, Science and technology
Abstract

2024 SEP 27 (NewsRx) -- By a News Reporter-Staff News Editor at Science Letter -- Researchers detail new data in science. According to news originating from Baylor College of Medicine [...]

Published
2024

13. Boundless Bio IPOs ecDNA Platform: BIOTECH: Filing Follows 3 Large Funding Rounds

Author

Clemetson, Jeff

Subjects
Bayer AG -- Securities, Going public (Securities), Financial markets, Corporations -- Finance, Cancer -- Genetic aspects, Extrachromosomal DNA, Pharmaceutical industry -- Securities, Company public offering, Company securities, Business, Business, regional
Abstract

SAN DIEGO Boundless Bio, Inc. is taking its innovative therapeutics directed against extrachromosomal DNA (ecDNA) - fragments of chromosomes that lead to oncogene amplified cancer - to the boundless opportunities [...]

Published
2024

14. Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024

Subjects
Conferences and conventions, Cancer -- Genetic aspects, Extrachromosomal DNA, Chief financial officers, Business, Business, international
Abstract

SAN DIEGO -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced [...]

Published
2024

15. Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024

Subjects
Oncology, Experimental, Societies, Chemotherapy, Cancer -- Chemotherapy -- Research, Extrachromosomal DNA, Associations, institutions, etc., Business, Business, international
Abstract

Findings support the ongoing development of BBI-355, a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1) in Phase 1/2 development, as a differentiated treatment approach for ecDNA-enabled oncogene amplified [...]

Published
2024

16. Boundless Bio Announces Pricing of Initial Public Offering

Subjects
Going public (Securities), Cancer -- Genetic aspects, Extrachromosomal DNA, Company public offering, Company securities, Business, Business, international
Abstract

SAN DIEGO -- Boundless Bio, Inc. (Nasdaq: BOLD), a clinical stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, [...]

Published
2024

19. Antigenic diversity in malaria parasites is maintained on extrachromosomal DNA

Subjects
Malaria, Extrachromosomal DNA, Plasmodium falciparum, Circular DNA, Physical fitness, Health
Abstract

2023 FEB 25 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- According to news reporting based on a preprint abstract, our journalists obtained [...]

Published
2023

21. Researchers' Work from Sun Yat-sen University Cancer Center Focuses on Personalized Medicine (Machine learning-based extrachromosomal DNA identification in large-scale cohorts reveals its clinical implications in cancer)

Subjects
Oncology, Experimental, Genetic research, Immunotherapy, Cancer -- Care and treatment -- Genetic aspects -- Research, Machine learning, Extrachromosomal DNA, Health
Abstract

2024 MAR 20 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Investigators publish new report on personalized medicine. According to news originating from Sun Yat-sen University [...]

Published
2024

23. Boundless Bio Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate VERZENIO[R] (abemaciclib) in Combination with BBI-355 in Patients with CDK4 or CDK6 Amplified Solid Tumors

Subjects
Eli Lilly and Co. -- Product development, Tumors, Cancer -- Genetic aspects, Clinical trials, Extrachromosomal DNA, Pharmaceutical industry -- Product development, Business, Business, international, Verzenio (Medication) -- Product development
Abstract

Combination of BBI-355 and abemaciclib to be evaluated in Boundless Bio's ongoing Phase 1/2 clinical trial (POTENTIATE) in patients with CDK4/6 amplifications SAN DIEGO -- Boundless Bio, a clinical stage, [...]

Published
2023

24. Boundless Bio Announces Clinical Trial Collaboration and Supply Agreement with Taiho Oncology to Evaluate LYTGOBI[R] (futibatinib) in Combination with BBI-355 in Patients with FGFR Amplified Solid Tumors

Subjects
Tumors, Cancer -- Genetic aspects, Clinical trials, Extrachromosomal DNA, Business, Business, international, Lytgobi (Medication) -- Product development
Abstract

Combination of BBI-355 and futibatinib to be evaluated in Boundless Bio's ongoing Phase 1/2 clinical trial (POTENTIATE) in patients with FGFR amplifications SAN DIEGO -- Boundless Bio, a clinical stage, [...]

Published
2023

25. Boundless Bio Issues Jami Rubin as Chief Financial Officer

Subjects
Financial analysts, Cancer -- Genetic aspects, Extrachromosomal DNA, Chief financial officers, Investment bankers, Venture capital companies, General interest, News, opinion and commentary
Abstract

SAN DIEGO: Boundless Bio, a clinical stage, next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) for patients with oncogene amplified cancers, today announced the appointment of [...]

Published
2023

27. To Present at the 2023 Jefferies Healthcare Conference is Boundless Bio

Subjects
Conferences and conventions, Cancer -- Genetic aspects, Extrachromosomal DNA, General interest, News, opinion and commentary
Abstract

SAN DIEGO: Boundless Bio, a clinical stage, next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) for patients with oncogene amplified cancers, announced that Chief Medical Officer, [...]

Published
2023

28. Boundless Bio to Present at the 2023 Jefferies Healthcare Conference

Subjects
Conferences and conventions, Cancer -- Genetic aspects, Extrachromosomal DNA, Business, Business, international
Abstract

SAN DIEGO -- Boundless Bio, a clinical stage, next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) for patients with oncogene amplified cancers, today announced that Chief [...]

Published
2023

29. Targeted profiling of human extrachromosomal DNA by CRISPR-CATCH

Subjects
Cancer, Extrachromosomal DNA, Physical fitness, Health
Abstract

2021 DEC 18 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- According to news reporting based on a preprint abstract, our journalists obtained [...]

Published
2021

31. Boundless Bio to Present at Stifel 2023 Virtual Targeted Oncology Days

Subjects
Cancer -- Genetic aspects, Extrachromosomal DNA, General interest, News, opinion and commentary
Abstract

SAN DIEGO: Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced that its President and Chief Executive Officer, [...]

Published
2023

32. Boundless Bio to Present at the Stifel 2023 Virtual Targeted Oncology Days

Subjects
Cancer -- Genetic aspects, Extrachromosomal DNA, Business, Business, international
Abstract

SAN DIEGO -- Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced that its President and Chief Executive [...]

Published
2023

33. Boundless Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference

Subjects
Conferences and conventions, Cancer -- Genetic aspects, Extrachromosomal DNA, General interest, News, opinion and commentary
Abstract

SAN DIEGO: Boundless Bio has issued the following news release: Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today [...]

Published
2023

34. Boundless Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference

Subjects
Conferences and conventions, Cancer -- Genetic aspects, Extrachromosomal DNA, Business, Business, international
Abstract

SAN DIEGO -- Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced that its Chief Business Officer, Neil [...]

Published
2023

40. Human Smc5/6 recognises transcription-generated positive DNA supercoils

Subjects
Molecular biology, Extrachromosomal DNA, Genetic transcription, Cells, Biological sciences, Health
Abstract

2023 MAY 23 (NewsRx) -- By a News Reporter-Staff News Editor at Life Science Weekly -- According to news reporting based on a preprint abstract, our journalists obtained the following [...]

Published
2023

42. Boundless Bio to Presented at the 41st Annual J.P. Morgan Healthcare Conference

Subjects
JPMorgan Chase & Co., Banking industry, Conferences and conventions, Cancer -- Genetic aspects, Extrachromosomal DNA, Banking industry, General interest, News, opinion and commentary
Abstract

SAN DIEGO: Boundless Bio. a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced that its Chief Executive Officer, Zachary Hornby, [...]

Published
2022

43. Boundless Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference

Subjects
JPMorgan Chase & Co., Conferences and conventions, Cancer -- Genetic aspects, Extrachromosomal DNA, Business, Business, international
Abstract

SAN DIEGO -- Boundless Bio. a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced that its Chief Executive Officer, Zachary [...]

Published
2022

44. Boundless Bio to Participate at Two Upcoming Investor Conferences

Subjects
Cancer -- Genetic aspects, Extrachromosomal DNA, General interest, News, opinion and commentary
Abstract

SAN DIEGO: BOUNDLESS BIO has issued the following news release: Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today [...]

Published
2022

45. Boundless Bio to Participate at Two Upcoming Investor Conferences

Subjects
Cancer -- Genetic aspects, Extrachromosomal DNA, Business, Business, international
Abstract

SAN DIEGO -- Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced that its Chief Executive Officer, Zachary [...]

Published
2022

47. DON CLEVELAND TO PRESENT 2022 E.B. WILSON LECTURE

Subjects
Genomics, Extrachromosomal DNA, Cells, News, opinion and commentary
Abstract

BETHESDA, Md. -- The following information was released by the American Society for Cell Biology ( ASCB): by Mary Spiro The American Society for Cell Biology (ASCB) is excited to [...]

Published
2022

48. Data on Cancer Reported by Researchers at University of California San Diego (UCSD) (Ampliconreconstructor Integrates Ngs and Optical Mapping To Resolve the Complex Structures of Focal Amplifications)

Subjects
Physical fitness, Cancer, Cancer research, Extrachromosomal DNA, Health, University of California
Abstract

2020 OCT 17 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Fresh data on Cancer are presented in a new report. According to [...]

Published
2020

49. Recent Research from University of California at San Diego Highlight Findings in Cancer (Circular Ecdna Promotes Accessible Chromatin and High Oncogene Expression)

Subjects
United States. National Institutes of Health, Genetic research, Physical fitness, Cancer genetics -- Genetic aspects, Cancer -- Genetic aspects, Cancer research, Extrachromosomal DNA, Chromatin, Anopheles, Genomics, Genetic regulation, DNA, Genes, Obesity, DNA sequencing, Genomes, Editors, Health, University of California, San Diego
Abstract

2020 JAN 4 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Cancer have been published. According to news reporting [...]

Published
2020

50. Team Led by Boundless Bio Scientific Founders Receives $25M Award to Better Understand Extrachromosomal DNA (ecDNA) Through Cancer Grand Challenges

Subjects
United States. National Cancer Institute, Cancer -- Genetic aspects, Extrachromosomal DNA, General interest, News, opinion and commentary
Abstract

SAN DIEGO: Boundless Bio has issued the following news release: Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today [...]

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results